Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Biodesix, Inc., a leading player in the precision medicine industry, is headquartered in the United States. Founded in 2010, the company has made significant strides in the development of innovative diagnostic solutions, particularly in the field of lung cancer. Biodesix focuses on utilising advanced genomic and proteomic technologies to provide actionable insights for oncologists, enhancing patient care through personalised treatment options.
The company’s core offerings include its proprietary blood-based tests, which are designed to identify specific biomarkers associated with lung cancer. This unique approach not only aids in early detection but also helps in tailoring therapies to individual patient profiles. Biodesix has established a strong market position, recognised for its commitment to improving patient outcomes and advancing the field of oncology diagnostics.
-9 vs industry average
Biodesix, Inc.’s score of 27 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Business Services is among the least carbon-intensive industries
The Business Services industry has reduced its overall emissions by 25% since 2018
No reported emissions data is available for Biodesix, Inc. yet.
Biodesix, Inc., headquartered in the United States, currently does not report any specific carbon emissions data, as indicated by the absence of available figures. However, the company is committed to addressing climate change through its participation in the Science Based Targets initiative (SBTi). Biodesix has set near-term targets, demonstrating its commitment to reducing emissions, although specific reduction targets have not been disclosed.
As part of the healthcare providers and services sector, Biodesix is actively working towards sustainability goals. The company is committed to implementing strategies that align with industry standards for climate action, reflecting a proactive approach to environmental responsibility.
While no absolute emissions figures are available, Biodesix's commitment to climate initiatives positions it as a forward-thinking organisation in the healthcare technology space, aiming to contribute positively to global climate efforts.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more